Clene
CLNN

$5.16

2.79%

Market Cap: $33.4M

About: Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).

Employees: 85

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

3,131% more call options, than puts

Call options by funds: $1.58M | Put options by funds: $49K

33% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 9

0.68% less ownership

Funds ownership: 5.94% [Q1] → 5.26% (-0.68%) [Q2]

16% less funds holding

Funds holding: 44 [Q1] → 37 (-7) [Q2]

26% less capital invested

Capital invested by funds: $3.25M [Q1] → $2.4M (-$841K) [Q2]

70% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 10

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$23

346%

upside

Avg. target

$57

1,005%

upside

High target

$140

2,613%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis 36% 1-year accuracy 97 / 266 met price target	501%upside $31	Buy Reiterated	16 Sept 2024
EF Hutton Jason Kolbert 43% 1-year accuracy 15 / 35 met price target	346%upside $23	Buy Maintained	16 Sept 2024
EF Hutton Jason Kolbert 43% 1-year accuracy 15 / 35 met price target	346%upside $23	Buy Initiated	10 Sept 2024
HC Wainwright & Co. Joseph Pantginis 36% 1-year accuracy 97 / 266 met price target	501%upside $31	Buy Maintained	9 Aug 2024
Canaccord Genuity Sumant Kulkarni 50% 1-year accuracy 12 / 24 met price target	1,722%upside $94	Buy Reiterated	6 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about CLNN published over the past 30 days

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), announced today that it will meet in-person with the U.S. Food and Drug Administration (FDA) before the end of November 2024 to discuss CNM-Au8 development for ALS.

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings.

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Zacks Investment Research

Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a Bet

The consensus price target hints at an 873.5% upside potential for Clene (CLNN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a Bet

Zacks Investment Research

Wall Street Analysts Believe Clene (CLNN) Could Rally 976.32%: Here's is How to Trade

The mean of analysts' price targets for Clene (CLNN) points to a 976.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Clene (CLNN) Could Rally 976.32%: Here's is How to Trade

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

LOS ANGELES, Aug. 08, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Zacks Investment Research

Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates

Clene Inc. (CLNN) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.60. This compares to loss of $2.40 per share a year ago.

Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

SALT LAKE CITY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its second quarter 2024 financial results and provided recent updates on its CNM-Au8® programs.

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, July 12, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.

Clene to Present at the Emerging Growth Conference

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

SALT LAKE CITY, July 11, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced plans to submit a briefing book by July 13 to the U.S. Food and Drug Administration (FDA) in advance of a granted Type C interaction. The purpose of the interaction with the FDA, to occur in the third quarter of 2024, is to receive feedback on the potential path to submission of a new drug application (NDA) for CNM-Au8® as a potential treatment for ALS via the accelerated approval pathway.

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Clene Announces 1-for-20 Reverse Stock Split

SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will effect a 1-for-20 reverse stock split at 12:01 a.m. Eastern Time, on July 11, 2024. Beginning with the opening of trading on July 11, 2024, Clene's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 185634201 and the Company's existing trading symbol “CLNN.” The CUSIP number for the Company's publicly traded warrants will not change.

Clene Announces 1-for-20 Reverse Stock Split

See News Rankings